www.fdanews.com/articles/85947-euflexxa-labeling-extended-to-include-room-temperature-storage
EUFLEXXA LABELING EXTENDED TO INCLUDE ROOM TEMPERATURE STORAGE
April 10, 2006
Ferring Pharmaceuticals Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved the Premarket Application (PMA) supplement for EUFLEXXA (highly purified hyaluronan) that allows the product to be stored at room temperature, as well as refrigerated. EUFLEXXA is a three-injection treatment given by physicians for the pain caused by knee osteoarthritis
(OA).
PR
Newswire